title: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
abstract: OBJECTIVE
  We evaluated etanercept, a human soluble tumor necrosis factor receptor: Fc fusion protein, for the treatment of active Crohn's disease.
  
  
  METHODS
  Forty-three patients with moderate to severe Crohn's disease were enrolled in an 8-week placebo-controlled trial. Patients were randomized to subcutaneous etanercept 25 mg or placebo twice weekly. The primary outcome measure was clinical response at week 4, defined as a decrease in the baseline Crohn's Disease Activity Index score > or =70 points or a Crohn's Disease Activity Index score <150 points.
  
  
  RESULTS
  At week 4, 39% of etanercept-treated patients had clinical response as compared with 45% of placebo-treated patients (P = 0.763). The frequency of common adverse events including headache, new injection site reaction, asthenia, abdominal pain, Crohn's disease-related anemia, and skin disorders was similar in both groups. Likewise, the frequency of severe or serious adverse events was similar in both groups.
  
  
  CONCLUSIONS
  Subcutaneous etanercept at a dose of 25 mg twice weekly is safe, but not effective, for the treatment of patients with moderate to severe Crohn's disease. The dose of etanercept administered in this study is that approved for rheumatoid arthritis. Higher doses or more frequent dosing may be required to attain a response in patients with active Crohn's disease.
authors.affiliation: The Mayo Clinic, Rochester, Minnesota 55905, USA. sandborn.william@mayo.edu
authors.forename: W J
authors.initials: WJ
authors.lastname: Sandborn
authors.forename: S B
authors.initials: SB
authors.lastname: Hanauer
authors.forename: S
authors.initials: S
authors.lastname: Katz
authors.forename: M
authors.initials: M
authors.lastname: Safdi
authors.forename: D G
authors.initials: DG
authors.lastname: Wolf
authors.forename: R D
authors.initials: RD
authors.lastname: Baerg
authors.forename: W J
authors.initials: WJ
authors.lastname: Tremaine
authors.forename: T
authors.initials: T
authors.lastname: Johnson
authors.forename: N N
authors.initials: NN
authors.lastname: Diehl
authors.forename: A R
authors.initials: AR
authors.lastname: Zinsmeister
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D000068800:Etanercept; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; C402162:CDP 571; D000069285:Infliximab; D000068800:Etanercept